董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Ramsay | 男 | Independent Director | 62 | 未披露 | 未持股 | 2026-10-06 |
| Kevin Tang | 男 | Chair of the Board,Chief Executive Officer and Director | 59 | 未披露 | 0.10 | 2026-10-06 |
| Kevin Tang | 男 | Chair of the Board,Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2026-10-06 |
| Craig Johnson | 男 | Independent Director | 65 | 未披露 | 未持股 | 2026-10-06 |
| Tina S. Nova | 女 | Independent Director | 72 | 未披露 | 未持股 | 2026-10-06 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Thomas Wei | 男 | Chief Scientific Officer | 50 | 未披露 | 未持股 | 2026-10-06 |
| Michael Hearne | 男 | Chief Financial Officer | 63 | 未披露 | 未持股 | 2026-10-06 |
| Kevin Tang | 男 | Chair of the Board,Chief Executive Officer and Director | 59 | 未披露 | 0.10 | 2026-10-06 |
| Stew Kroll | 男 | Chief Development Officer | 68 | 未披露 | 未持股 | 2026-10-06 |
| Ryan Cole | 男 | Chief Operating Officer | 39 | 未披露 | 未持股 | 2026-10-06 |
| Kevin Tang | 男 | Chair of the Board,Chief Executive Officer and Director | 59 | 未披露 | 未持股 | 2026-10-06 |
董事简历
中英对照 | 中文 | 英文- David Ramsay
-
David Ramsay，自2019年起担任董事。他还担任Exuma Biotech, Inc.的董事。从2018年2月到2018年10月被Allergan plc收购，Ramsay先生担任Bonti, Inc.的高级副总裁兼首席财务官，从2015年到2018年2月担任董事。从2003年到2015年，他在Halozyme Therapeutics, Inc.担任多个职位，最近担任首席财务官。从自2004年起担任Vanda的董事。Ramsay先生曾担任Care Capital，LLC的合伙人，2000年共同创立的公司。2000年到2003年，他担任Lathian Systems, Inc.的副总裁、首席财务官。从1998年到2000年，他担任Valeant Pharmaceuticals International, Inc.（前身为ICN Pharmaceuticals, Inc.)的副总裁、财务主管和公司财务总监。Ramsay先生的职业生涯始于Deloitte & Touche LLP.Ramsay先生持有the University of California, Berkeley的工商管理学士学位，the Wharton School of the University of Pennsylvania的金融和战略管理工商管理硕士学位，是加州的注册会计师（不活跃）。
David Ramsay has served as a director since 2019. He also serves as a director of Exuma Biotech, Inc. and a director of Savara, Inc. From February 2018 through its acquisition by Allergan plc in October 2018 Mr. Ramsay served as Senior Vice President and Chief Financial Officer, and from 2015 to February 2018 served as a director, of Bonti, Inc. From 2003 to 2015 he held various positions at Halozyme Therapeutics, Inc., most recently serving as Chief Financial Officer. From 2000 to 2003 Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc. From 1998 to 2000 he served as Vice President, Treasurer and Director, Corporate Finance at Valeant Pharmaceuticals International, Inc. formerly ICN Pharmaceuticals, Inc.. Mr. Ramsay started his career at Deloitte & Touche LLP. Mr. Ramsay received a B.S. in business administration from the University of California, Berkeley, an MBA in finance and strategic management from the Wharton School of the University of Pennsylvania and is a Certified Public Accountant (inactive) in the state of California. - David Ramsay，自2019年起担任董事。他还担任Exuma Biotech, Inc.的董事。从2018年2月到2018年10月被Allergan plc收购，Ramsay先生担任Bonti, Inc.的高级副总裁兼首席财务官，从2015年到2018年2月担任董事。从2003年到2015年，他在Halozyme Therapeutics, Inc.担任多个职位，最近担任首席财务官。从自2004年起担任Vanda的董事。Ramsay先生曾担任Care Capital，LLC的合伙人，2000年共同创立的公司。2000年到2003年，他担任Lathian Systems, Inc.的副总裁、首席财务官。从1998年到2000年，他担任Valeant Pharmaceuticals International, Inc.（前身为ICN Pharmaceuticals, Inc.)的副总裁、财务主管和公司财务总监。Ramsay先生的职业生涯始于Deloitte & Touche LLP.Ramsay先生持有the University of California, Berkeley的工商管理学士学位，the Wharton School of the University of Pennsylvania的金融和战略管理工商管理硕士学位，是加州的注册会计师（不活跃）。
- David Ramsay has served as a director since 2019. He also serves as a director of Exuma Biotech, Inc. and a director of Savara, Inc. From February 2018 through its acquisition by Allergan plc in October 2018 Mr. Ramsay served as Senior Vice President and Chief Financial Officer, and from 2015 to February 2018 served as a director, of Bonti, Inc. From 2003 to 2015 he held various positions at Halozyme Therapeutics, Inc., most recently serving as Chief Financial Officer. From 2000 to 2003 Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc. From 1998 to 2000 he served as Vice President, Treasurer and Director, Corporate Finance at Valeant Pharmaceuticals International, Inc. formerly ICN Pharmaceuticals, Inc.. Mr. Ramsay started his career at Deloitte & Touche LLP. Mr. Ramsay received a B.S. in business administration from the University of California, Berkeley, an MBA in finance and strategic management from the Wharton School of the University of Pennsylvania and is a Certified Public Accountant (inactive) in the state of California.
- Kevin Tang
-
Kevin Tang，美国公民，唐氏资本管理公司经理。
Kevin Tang, a United States citizen.Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University. - Kevin Tang，美国公民，唐氏资本管理公司经理。
- Kevin Tang, a United States citizen.Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.
- Kevin Tang
-
Kevin Tang自2026年8月14日起担任Tang Capital Acquisition Corp.的董事会主席兼首席执行官。唐先生是唐资本管理有限责任公司的总裁，这是他于2002年创立的一家专注于生命科学的投资公司。自2026年3月起担任首席执行官，自2024年起担任Aurinia Pharmaceuticals Inc.董事会主席。自2014年起，通过2022年被亚邦丝医疗，Inc.收购，唐先生担任La Jolla Pharmaceutical Company的董事长。2013年，他创立了Odonate治疗公司，并担任该公司的董事长兼首席执行官至2022年。Tang co先生于2009年创立了Heron Therapeutics公司，并于2009年至2012年担任董事，2012年至2020年担任董事长。从2009年通过2010年被Endo，Inc.（现为Keenova Therapeutics plc）收购，担任Penwest Pharmaceuticals Co.的董事。2006年，Tang先生co创立了Ardea生物科技公司，并通过2012年被阿斯利康 PLC收购担任董事。从2001年到2008年，他担任Trimeris，Inc.的董事。从1993年到2001年，唐先生是投资银行公司德意志银行Alex Brown，Inc.的研究分析师，最近担任董事总经理和该公司生命科学研究小组的负责人。唐先生获得了杜克大学的学士学位。
Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University. - Kevin Tang自2026年8月14日起担任Tang Capital Acquisition Corp.的董事会主席兼首席执行官。唐先生是唐资本管理有限责任公司的总裁，这是他于2002年创立的一家专注于生命科学的投资公司。自2026年3月起担任首席执行官，自2024年起担任Aurinia Pharmaceuticals Inc.董事会主席。自2014年起，通过2022年被亚邦丝医疗，Inc.收购，唐先生担任La Jolla Pharmaceutical Company的董事长。2013年，他创立了Odonate治疗公司，并担任该公司的董事长兼首席执行官至2022年。Tang co先生于2009年创立了Heron Therapeutics公司，并于2009年至2012年担任董事，2012年至2020年担任董事长。从2009年通过2010年被Endo，Inc.（现为Keenova Therapeutics plc）收购，担任Penwest Pharmaceuticals Co.的董事。2006年，Tang先生co创立了Ardea生物科技公司，并通过2012年被阿斯利康 PLC收购担任董事。从2001年到2008年，他担任Trimeris，Inc.的董事。从1993年到2001年，唐先生是投资银行公司德意志银行Alex Brown，Inc.的研究分析师，最近担任董事总经理和该公司生命科学研究小组的负责人。唐先生获得了杜克大学的学士学位。
- Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.
- Craig Johnson
-
Craig Johnson，自2013年9月以来，是本公司董事会的一位成员。目前在数个生命科学公司的董事会任职。他目前是以下公司的一位董事：一家在纳斯达克（NASDAQ）上市的特殊医药公司- Heron Therapeutics股份有限公司、一家在纳斯达克（NASDAQ）上市的生物医药公司- Adamis医药公司和一家在纳斯达克（NASDAQ）上市的生物医药公司- La Jolla医药公司。他还曾在2008一直到Ardea Biosciences股份有限公司2012年被出售给阿斯利康（AstraZeneca PLC）之前，是一家纳斯达克（NASDAQ）上市生物技术公司- Ardea Biosciences股份有限公司的一位前董事。除了他的董事会任职，他曾在2012年以来，担任Daisas Medical有限责任公司的顾问。2011-2012年期间，他曾是PURE Bioscience股份有限公司的财务总监；2010-2011年期间，曾在NovaDel Pharma股份有限公司担任高级副总裁和财务总监。2004年一直到2009年TorreyPines Therapeutics股份有限公司被出售给Raptor Pharmaceuticals Corp.之前，在TorreyPines Therapeutics股份有限公司担任副总裁和财务总监；随后于2009-2010年期间，是Raptor医药公司一个独资子公司的副总裁。他曾担任数个职位，包括1994-2004年期间在MitoKor股份有限公司担任财务总监和业务高级副总裁。在1994年之前，他曾在数个早期科技公司担任数个高级财务职位，还曾在Price Waterhouse的一位注册会计师。Johnson先生是从Michigan大学Dearborn分校获得他的工商管理学士学位的。
Craig Johnson has served as a member of Board of Directors since September 2013. Mr. Johnson serves on the boards of directors for several life science companies. He is currently a director for Heron Therapeutics, Inc., a NASDAQ-listed specialty pharmaceutical company, a position he has held since January 2014 as well as for La Jolla Pharmaceutical Company, a NASDAQ-listed biopharmaceutical company, a position he has held since October 2013. Mr. Johnson also serves as a director of GenomeDx Biosciences, a privately held biotechnology company, a position he has held since October 2015. Mr. Johnson also served as a past director of Adamis Pharmaceuticals Corporation, a NASDAQ-listed biopharmaceutical company, from 2011 to 2014 as well as Ardea Biosciences, Inc., a NASDAQ-listed biotechnology company, from 2008 until its sale to AstraZeneca PLC in June 2012. From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009 and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994 Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn. - Craig Johnson，自2013年9月以来，是本公司董事会的一位成员。目前在数个生命科学公司的董事会任职。他目前是以下公司的一位董事：一家在纳斯达克（NASDAQ）上市的特殊医药公司- Heron Therapeutics股份有限公司、一家在纳斯达克（NASDAQ）上市的生物医药公司- Adamis医药公司和一家在纳斯达克（NASDAQ）上市的生物医药公司- La Jolla医药公司。他还曾在2008一直到Ardea Biosciences股份有限公司2012年被出售给阿斯利康（AstraZeneca PLC）之前，是一家纳斯达克（NASDAQ）上市生物技术公司- Ardea Biosciences股份有限公司的一位前董事。除了他的董事会任职，他曾在2012年以来，担任Daisas Medical有限责任公司的顾问。2011-2012年期间，他曾是PURE Bioscience股份有限公司的财务总监；2010-2011年期间，曾在NovaDel Pharma股份有限公司担任高级副总裁和财务总监。2004年一直到2009年TorreyPines Therapeutics股份有限公司被出售给Raptor Pharmaceuticals Corp.之前，在TorreyPines Therapeutics股份有限公司担任副总裁和财务总监；随后于2009-2010年期间，是Raptor医药公司一个独资子公司的副总裁。他曾担任数个职位，包括1994-2004年期间在MitoKor股份有限公司担任财务总监和业务高级副总裁。在1994年之前，他曾在数个早期科技公司担任数个高级财务职位，还曾在Price Waterhouse的一位注册会计师。Johnson先生是从Michigan大学Dearborn分校获得他的工商管理学士学位的。
- Craig Johnson has served as a member of Board of Directors since September 2013. Mr. Johnson serves on the boards of directors for several life science companies. He is currently a director for Heron Therapeutics, Inc., a NASDAQ-listed specialty pharmaceutical company, a position he has held since January 2014 as well as for La Jolla Pharmaceutical Company, a NASDAQ-listed biopharmaceutical company, a position he has held since October 2013. Mr. Johnson also serves as a director of GenomeDx Biosciences, a privately held biotechnology company, a position he has held since October 2015. Mr. Johnson also served as a past director of Adamis Pharmaceuticals Corporation, a NASDAQ-listed biopharmaceutical company, from 2011 to 2014 as well as Ardea Biosciences, Inc., a NASDAQ-listed biotechnology company, from 2008 until its sale to AstraZeneca PLC in June 2012. From 2011 to 2012 he was Chief Financial Officer of PURE Bioscience, Inc., and from 2010 to 2011 he was Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. Mr. Johnson served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc. from 2004 until its sale to Raptor Pharmaceuticals Corp. in 2009 and then as Vice President of a wholly-owned subsidiary of Raptor Pharmaceutical Corp. from 2009 to 2010. He held several positions, including Chief Financial Officer and Senior Vice President of Operations, at MitoKor, Inc. from 1994 to 2004. Prior to 1994 Mr. Johnson held senior financial positions with several early-stage technology companies, and also practiced as a Certified Public Accountant with Price Waterhouse. Mr. Johnson received his B.B.A. in accounting from the University of Michigan-Dearborn.
- Tina S. Nova
-
Tina S. Nova博士自2014年4月成为董事会的成员，同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.，这是一家医药实验室诊断公司，她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix，担任Genoptix的首席执行官，同时是Genoptix董事会成员。此前，Nova先生联合创建了Nanogen, Inc.，Nanogen, Inc.是一家分子诊断测试的提供商，她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前，Nova博士担任Selective Genetics的首席运营官，这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.（Eli Lilly & Company的前子公司）担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校（niversity of California, Irvine）获得生物科学学士学位。从加州大学里弗赛德分校（University of California, Riverside）获得生物化学博士学位。
Tina S. Nova has extensive experience in the creation of start up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co founded a number of early stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc. - Tina S. Nova博士自2014年4月成为董事会的成员，同时是薪酬委员会的成员。Nova博士联合创建了Genoptix, Inc.，这是一家医药实验室诊断公司，她从2000年到2014年4月退休在Genoptix, Inc.担任总裁。Nova博士从2000年到2011年2月Novartis AG收购Genoptix，担任Genoptix的首席执行官，同时是Genoptix董事会成员。此前，Nova先生联合创建了Nanogen, Inc.，Nanogen, Inc.是一家分子诊断测试的提供商，她从1994年到2000年担任Nanogen, Inc.的首席运营官。在加入Nanogen前，Nova博士担任Selective Genetics的首席运营官，这是一家生物技术公司。Nova博士还在Ligand Pharmaceuticals Incorporated和Hybritech, Inc.（Eli Lilly & Company的前子公司）担任各种研究和管理职务。Nova博士还任职于Adamis Pharmaceuticals Corporation和Arena Pharmaceuticals, Inc.的董事会。Nova博士从加州大学欧文分校（niversity of California, Irvine）获得生物科学学士学位。从加州大学里弗赛德分校（University of California, Riverside）获得生物化学博士学位。
- Tina S. Nova has extensive experience in the creation of start up companies and the commercialization of products with a focus on molecular diagnostics. Dr. Nova spent 15 years as the co founder, President and CEO of the publicly traded company, Genoptix Medical Laboratories, from inception to its acquisition by Novartis Pharmaceuticals in 2011. She has worked for, managed, raised capital and co founded a number of early stage innovative biotechnology companies in San Diego including Nanogen, Inc., Ligand Pharmaceuticals and Hybritech, Inc.
高管简历
中英对照 | 中文 | 英文- Thomas Wei
Thomas Wei自2015年起担任Ordonate Therapeutics，Llc研究和战略高级副总裁。Wei先生还担任Tang Capital Management，Llc董事总经理。Tang Capital Management，Llc是一家专注于生命科学的投资公司，他于2015年加入Tang Capital Management，Llc.2009年至2015年，他担任Jefferies LLC的常务董事和生物技术股权研究分析师。2003年至2009年，Wei先生担任Piper Jaffray的生物技术股权研究分析师，最近担任常务董事。1998年至2003年，Wei先生是德意志银行股份有限公司和Deutsche Bank AG和Harkness & Hill Inc.的生物技术股票研究分析师。Wei先生获得了哈佛大学的生物化学学士学位和牛津大学的工商管理硕士学位。
Thomas Wei has served as Tang Capital Acquisition Corp.'s Chief Scientific Officer since August 14, 2026. Mr. Wei has served as Managing Director of Tang Capital Management, LLC since 2015. He has served as Chief Scientific Officer of Aurinia Pharmaceuticals Inc. since March 2026. From 2015 to 2021, Mr. Wei served in various positions at Odonate Therapeutics, Inc., most recently serving as Chief Scientific Officer. From 2009 to 2015, he served in various positions at Jefferies LLC, most recently serving as Managing Director. From 2003 to 2009, Mr. Wei served in various positions at Piper Jaffray Companies (now Piper Sandler Companies), most recently serving as Managing Director. From 1998 to 2003, he served as a biotechnology equity research analyst at Deutsche Bank AG and Adams, Harkness & Hill, Inc. (now Canaccord Genuity Group Inc.). Mr. Wei received an A.B. degree from Harvard University and an M.B.A. degree from Oxford University.- Thomas Wei自2015年起担任Ordonate Therapeutics，Llc研究和战略高级副总裁。Wei先生还担任Tang Capital Management，Llc董事总经理。Tang Capital Management，Llc是一家专注于生命科学的投资公司，他于2015年加入Tang Capital Management，Llc.2009年至2015年，他担任Jefferies LLC的常务董事和生物技术股权研究分析师。2003年至2009年，Wei先生担任Piper Jaffray的生物技术股权研究分析师，最近担任常务董事。1998年至2003年，Wei先生是德意志银行股份有限公司和Deutsche Bank AG和Harkness & Hill Inc.的生物技术股票研究分析师。Wei先生获得了哈佛大学的生物化学学士学位和牛津大学的工商管理硕士学位。
- Thomas Wei has served as Tang Capital Acquisition Corp.'s Chief Scientific Officer since August 14, 2026. Mr. Wei has served as Managing Director of Tang Capital Management, LLC since 2015. He has served as Chief Scientific Officer of Aurinia Pharmaceuticals Inc. since March 2026. From 2015 to 2021, Mr. Wei served in various positions at Odonate Therapeutics, Inc., most recently serving as Chief Scientific Officer. From 2009 to 2015, he served in various positions at Jefferies LLC, most recently serving as Managing Director. From 2003 to 2009, Mr. Wei served in various positions at Piper Jaffray Companies (now Piper Sandler Companies), most recently serving as Managing Director. From 1998 to 2003, he served as a biotechnology equity research analyst at Deutsche Bank AG and Adams, Harkness & Hill, Inc. (now Canaccord Genuity Group Inc.). Mr. Wei received an A.B. degree from Harvard University and an M.B.A. degree from Oxford University.
- Michael Hearne
Michael Hearne自2018年起担任Ordonate Therapeutics，Inc.首席财务官，此前于2015年至2018年担任财务和会计副总裁。自2015年起，他担任Tang Capital Management，LLC的首席财务官。Tang Capital Management，LLC是一家专注于生命科学的投资公司，也是该公司的附属公司。自2020年以来，Hearne先生还担任生物制药公司La Jolla Pharmaceutical Company的首席财务官。2014年至2015年，他在Weaver&Tidwell有限责任合伙公司担任合伙人。Hearne先生在Coopers&Lybrand开始了他的公共会计生涯。Hearne先生获得了Brigham Young大学的会计学学士学位和会计学、税务硕士学位，是加利福尼亚州的注册会计师。
Michael Hearne has served as our Chief Financial Officer since 2020. Since 2015 he has served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company. Since 2015 Mr. Hearne has also held various positions at Odonate Therapeutics, Inc., most recently serving as Chief Financial Officer since 2018. From 2014 to 2015 he served as a partner at Weaver & Tidwell, LLP. Mr. Hearne started his career in public accounting at Coopers & Lybrand. Mr. Hearne received a B.S. degree in accounting and a masters of accountancy, taxation from Brigham Young University and is a Certified Public Accountant inactive in the state of California.- Michael Hearne自2018年起担任Ordonate Therapeutics，Inc.首席财务官，此前于2015年至2018年担任财务和会计副总裁。自2015年起，他担任Tang Capital Management，LLC的首席财务官。Tang Capital Management，LLC是一家专注于生命科学的投资公司，也是该公司的附属公司。自2020年以来，Hearne先生还担任生物制药公司La Jolla Pharmaceutical Company的首席财务官。2014年至2015年，他在Weaver&Tidwell有限责任合伙公司担任合伙人。Hearne先生在Coopers&Lybrand开始了他的公共会计生涯。Hearne先生获得了Brigham Young大学的会计学学士学位和会计学、税务硕士学位，是加利福尼亚州的注册会计师。
- Michael Hearne has served as our Chief Financial Officer since 2020. Since 2015 he has served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company. Since 2015 Mr. Hearne has also held various positions at Odonate Therapeutics, Inc., most recently serving as Chief Financial Officer since 2018. From 2014 to 2015 he served as a partner at Weaver & Tidwell, LLP. Mr. Hearne started his career in public accounting at Coopers & Lybrand. Mr. Hearne received a B.S. degree in accounting and a masters of accountancy, taxation from Brigham Young University and is a Certified Public Accountant inactive in the state of California.
- Kevin Tang
Kevin Tang，美国公民，唐氏资本管理公司经理。
Kevin Tang, a United States citizen.Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.- Kevin Tang，美国公民，唐氏资本管理公司经理。
- Kevin Tang, a United States citizen.Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.
- Stew Kroll
Stew Kroll自2026年8月14日起担任Tang Capital Acquisition Corp.的首席开发官。自2016年以来，Kroll先生曾在Tang Capital Management，LLC担任多个职位，最近担任董事总经理。自2025年起担任Aurinia制药 Inc.的首席开发官。从2017年到2022年被亚邦丝医疗，Inc.收购，Kroll先生曾在La Jolla Pharmaceutical Company担任多个职位，最近担任首席发展官。2016年至2021年，他曾在Odonate Therapeutics, Inc.担任多个职位，最近担任首席开发官。2005年至2016年，Kroll先生曾在Threshold Pharmaceuticals，Inc.担任多个职位，最近担任首席运营官。2000年至2005年，他在Corixa Corporation（现GSK plc）担任生物统计学高级总监。从1997年到2000年被Corixa Corporation收购，Kroll先生在Coulter Pharmaceutical，Inc.担任过多个职位，最近担任生物统计总监。Kroll先生获得了加州大学伯克利分校的学士学位和硕士学位。
Stew Kroll has served as Tang Capital Acquisition Corp.'s Chief Development Officer since August 14, 2026. Mr. Kroll has served in various positions at Tang Capital Management, LLC since 2016, most recently serving as Managing Director. He has served as Chief Development Officer of Aurinia Pharmaceuticals Inc. since 2025. From 2017 through its acquisition by Innoviva, Inc. in 2022, Mr. Kroll served in various positions at La Jolla Pharmaceutical Company, most recently serving as Chief Development Officer. From 2016 to 2021, he served in various positions at Odonate Therapeutics, Inc., most recently serving as Chief Development Officer. From 2005 to 2016, Mr. Kroll served in various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation (now GSK plc). From 1997 through its acquisition by Corixa Corporation in 2000, Mr. Kroll served in various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. Mr. Kroll received a B.A. degree and an M.A. degree from the University of California, Berkeley.- Stew Kroll自2026年8月14日起担任Tang Capital Acquisition Corp.的首席开发官。自2016年以来，Kroll先生曾在Tang Capital Management，LLC担任多个职位，最近担任董事总经理。自2025年起担任Aurinia制药 Inc.的首席开发官。从2017年到2022年被亚邦丝医疗，Inc.收购，Kroll先生曾在La Jolla Pharmaceutical Company担任多个职位，最近担任首席发展官。2016年至2021年，他曾在Odonate Therapeutics, Inc.担任多个职位，最近担任首席开发官。2005年至2016年，Kroll先生曾在Threshold Pharmaceuticals，Inc.担任多个职位，最近担任首席运营官。2000年至2005年，他在Corixa Corporation（现GSK plc）担任生物统计学高级总监。从1997年到2000年被Corixa Corporation收购，Kroll先生在Coulter Pharmaceutical，Inc.担任过多个职位，最近担任生物统计总监。Kroll先生获得了加州大学伯克利分校的学士学位和硕士学位。
- Stew Kroll has served as Tang Capital Acquisition Corp.'s Chief Development Officer since August 14, 2026. Mr. Kroll has served in various positions at Tang Capital Management, LLC since 2016, most recently serving as Managing Director. He has served as Chief Development Officer of Aurinia Pharmaceuticals Inc. since 2025. From 2017 through its acquisition by Innoviva, Inc. in 2022, Mr. Kroll served in various positions at La Jolla Pharmaceutical Company, most recently serving as Chief Development Officer. From 2016 to 2021, he served in various positions at Odonate Therapeutics, Inc., most recently serving as Chief Development Officer. From 2005 to 2016, Mr. Kroll served in various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation (now GSK plc). From 1997 through its acquisition by Corixa Corporation in 2000, Mr. Kroll served in various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. Mr. Kroll received a B.A. degree and an M.A. degree from the University of California, Berkeley.
- Ryan Cole
Ryan Cole自2026年8月14日起担任Tang Capital Acquisition Corp.的首席运营官。自2014年以来，Cole先生曾在Tang Capital Management，LLC担任多个职位，最近担任首席运营官。自2026年3月起担任Aurinia制药公司首席运营官。2014年至2021年，Cole先生曾在Odonate Therapeutics, Inc.担任多个职位，最近担任运营高级副总裁。2012年至2014年，担任生命科学（现赛默飞世尔科技公司）并购业务高级金融分析师。从2009年到2012年，科尔先生曾在安永会计师事务所担任多个职位，最近担任高级、鉴证和咨询服务。Cole先生在圣克拉拉大学获得学士学位，是加利福尼亚州的注册会计师（非在职）。
Ryan Cole has served as Tang Capital Acquisition Corp.'s Chief Operating Officer since August 14, 2026. Mr. Cole has served in various positions at Tang Capital Management, LLC since 2014, most recently serving as Chief Operating Officer. He has served as Chief Operating Officer of Aurinia Pharmaceuticals Inc. since March 2026. From 2014 to 2021, Mr. Cole served in various positions at Odonate Therapeutics, Inc., most recently serving as Senior Vice President of Operations. From 2012 to 2014, he served as Senior Financial Analyst, Mergers and Acquisitions at Life Technologies Corporation (now Thermo Fisher Scientific Inc.). From 2009 to 2012, Mr. Cole served in various positions at Ernst & Young LLP, most recently serving as Senior, Assurance and Advisory Services. Mr. Cole received a B.S. degree from Santa Clara University and is a Certified Public Accountant (inactive) in the State of California.- Ryan Cole自2026年8月14日起担任Tang Capital Acquisition Corp.的首席运营官。自2014年以来，Cole先生曾在Tang Capital Management，LLC担任多个职位，最近担任首席运营官。自2026年3月起担任Aurinia制药公司首席运营官。2014年至2021年，Cole先生曾在Odonate Therapeutics, Inc.担任多个职位，最近担任运营高级副总裁。2012年至2014年，担任生命科学（现赛默飞世尔科技公司）并购业务高级金融分析师。从2009年到2012年，科尔先生曾在安永会计师事务所担任多个职位，最近担任高级、鉴证和咨询服务。Cole先生在圣克拉拉大学获得学士学位，是加利福尼亚州的注册会计师（非在职）。
- Ryan Cole has served as Tang Capital Acquisition Corp.'s Chief Operating Officer since August 14, 2026. Mr. Cole has served in various positions at Tang Capital Management, LLC since 2014, most recently serving as Chief Operating Officer. He has served as Chief Operating Officer of Aurinia Pharmaceuticals Inc. since March 2026. From 2014 to 2021, Mr. Cole served in various positions at Odonate Therapeutics, Inc., most recently serving as Senior Vice President of Operations. From 2012 to 2014, he served as Senior Financial Analyst, Mergers and Acquisitions at Life Technologies Corporation (now Thermo Fisher Scientific Inc.). From 2009 to 2012, Mr. Cole served in various positions at Ernst & Young LLP, most recently serving as Senior, Assurance and Advisory Services. Mr. Cole received a B.S. degree from Santa Clara University and is a Certified Public Accountant (inactive) in the State of California.
- Kevin Tang
Kevin Tang自2026年8月14日起担任Tang Capital Acquisition Corp.的董事会主席兼首席执行官。唐先生是唐资本管理有限责任公司的总裁，这是他于2002年创立的一家专注于生命科学的投资公司。自2026年3月起担任首席执行官，自2024年起担任Aurinia Pharmaceuticals Inc.董事会主席。自2014年起，通过2022年被亚邦丝医疗，Inc.收购，唐先生担任La Jolla Pharmaceutical Company的董事长。2013年，他创立了Odonate治疗公司，并担任该公司的董事长兼首席执行官至2022年。Tang co先生于2009年创立了Heron Therapeutics公司，并于2009年至2012年担任董事，2012年至2020年担任董事长。从2009年通过2010年被Endo，Inc.（现为Keenova Therapeutics plc）收购，担任Penwest Pharmaceuticals Co.的董事。2006年，Tang先生co创立了Ardea生物科技公司，并通过2012年被阿斯利康 PLC收购担任董事。从2001年到2008年，他担任Trimeris，Inc.的董事。从1993年到2001年，唐先生是投资银行公司德意志银行Alex Brown，Inc.的研究分析师，最近担任董事总经理和该公司生命科学研究小组的负责人。唐先生获得了杜克大学的学士学位。
Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.- Kevin Tang自2026年8月14日起担任Tang Capital Acquisition Corp.的董事会主席兼首席执行官。唐先生是唐资本管理有限责任公司的总裁，这是他于2002年创立的一家专注于生命科学的投资公司。自2026年3月起担任首席执行官，自2024年起担任Aurinia Pharmaceuticals Inc.董事会主席。自2014年起，通过2022年被亚邦丝医疗，Inc.收购，唐先生担任La Jolla Pharmaceutical Company的董事长。2013年，他创立了Odonate治疗公司，并担任该公司的董事长兼首席执行官至2022年。Tang co先生于2009年创立了Heron Therapeutics公司，并于2009年至2012年担任董事，2012年至2020年担任董事长。从2009年通过2010年被Endo，Inc.（现为Keenova Therapeutics plc）收购，担任Penwest Pharmaceuticals Co.的董事。2006年，Tang先生co创立了Ardea生物科技公司，并通过2012年被阿斯利康 PLC收购担任董事。从2001年到2008年，他担任Trimeris，Inc.的董事。从1993年到2001年，唐先生是投资银行公司德意志银行Alex Brown，Inc.的研究分析师，最近担任董事总经理和该公司生命科学研究小组的负责人。唐先生获得了杜克大学的学士学位。
- Kevin Tang has served as Tang Capital Acquisition Corp.'s Chair of the Board and Chief Executive Officer since August 14, 2026. Mr. Tang is President of Tang Capital Management, LLC, a life sciences focused investment company he founded in 2002. He has served as Chief Executive Officer since March 2026 and as Chair of the Board since 2024 of Aurinia Pharmaceuticals Inc. From 2014 through its acquisition by Innoviva, Inc. in 2022, Mr. Tang served as Chairman of La Jolla Pharmaceutical Company. In 2013, he founded Odonate Therapeutics, Inc. and served as its Chairman and Chief Executive Officer through 2022. Mr. Tang co founded Heron Therapeutics, Inc. in 2009 and served as Director from 2009 to 2012 and Chairman from 2012 to 2020. From 2009 through its acquisition by Endo, Inc. (now Keenova Therapeutics plc) in 2010, he served as Director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co founded Ardea Biosciences, Inc. and served as a Director through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he served as a Director of Trimeris, Inc. From 1993 to 2001, Mr. Tang was a research analyst at Deutsche Banc Alex Brown, Inc., an investment banking firm, and most recently was a Managing Director and head of the firm's Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.